Canada approves Moderna’s Covid-19 vaccine
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
It will also manage test result documentation for employees who are not vaccinated, sending weekly reminders and employer notification
It comes with a prime focus on infection control and patient flow as the primary infrastructure design aspects - the need of the hour and must-have during a pandemic.
Initially launched in Europe, this new service gives customers access to a range of digital health services and medical professionals and is part of its Digital Access to Care Initiative
Godrej and Boyce and Isgec Engineering have confirmed receiving the orders
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
Subscribe To Our Newsletter & Stay Updated